Progestational steroid(gestonorone caproate)による前立腺肥大症の治療

Abstract

1) SH 582 (gestonorone caproate) was used in 11 cases of prostatic hypertrophy (7 in the first or second stage, and 4 in the third stage). a) Subjective symptoms were improved in 6 cases and unchanged in 1 case with hypertrophy of the first or second stage. b) Residual urine volume was reduced in 6 cases and unchanged in 1 case with hypertrophy of the first or second stage. None of the cases in the third stage showed any favorable change in residual urine volume. c) Strength of urinary flow was improved in 5 and unchanged in 2 cases with hypertrophy of the first or second stage. None of the cases in the third stage showed any improvement in strength of urinary flow. d) SH 582 is to be used for prostatic hypertrophy of the first or second stage. We think that it must be administered at weekly doses of 400 mg for more than 3 months. e) There were no side-effects at all. 2) SH 582, when administered to rats, did not produce such an atrophic change of the prostate and testis as is observed after estrogen administration.